This article was published online on [28 December 2010]. An error was subsequently identified in Abstract. This notice is included in the online and print versions to indicate that both have been corrected [6 January 2011 ].
Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents†
Article first published online: 28 DEC 2010
Copyright © 2010 John Wiley & Sons, Ltd.
Volume 21, Issue 3, pages 238–251, March 2012
How to Cite
Neumann, P. J., Cohen, J. T., Hammitt, J. K., Concannon, T. W., Auerbach, H. R., Fang, C. and Kent, D. M. (2012), Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ., 21: 238–251. doi: 10.1002/hec.1704
- Issue published online: 23 JAN 2012
- Article first published online: 28 DEC 2010
- Manuscript Accepted: 23 NOV 2010
- Manuscript Revised: 27 OCT 2010
- Manuscript Received: 11 MAY 2010
- predictive tests;
- Alzheimer's disease;
We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet-based survey to a random sample of adult US respondents. Each respondent answered questions about two different scenarios, each of which specified: one of four randomly selected diseases (Alzheimer's, arthritis, breast cancer, or prostate cancer); an ex ante risk of developing the disease (randomly designated 10 or 25%); and test accuracy (randomly designated perfect or ‘not perfectly accurate’). Willingness-to-pay (WTP) was elicited with a double-bounded, dichotomous-choice approach. Of 1463 respondents who completed the survey, most (70-88%, depending on the scenario) were inclined to take the test. Inclination to take the test was lower for Alzheimer's and higher for prostate cancer compared with arthritis, and rose somewhat with disease prevalence and for the perfect versus imperfect test [Correction made here after initial online publication.]. Median WTP varied from $109 for the imperfect arthritis test to $263 for the perfect prostate cancer test. Respondents' preferences for predictive testing, even in the absence of direct treatment consequences, reflected health and non-health related factors, and suggests that conventional cost-effectiveness analyses may underestimate the value of testing. Copyright © 2010 John Wiley & Sons, Ltd.